A German biotechnology company secured a prime-time presentation slot at a major European oncology conference to share early data from a small clinical study. The company presented findings from a Phase 1 trial involving just 16 patients, a presentation that typically goes to practice-changing trials with much larger participant pools.
Oncologist Sapna Patel explained that the experimental cell therapy caused tumors to shrink in every one of the 16 participants. All patients in the study had uveal melanoma, a rare form of eye cancer. While the results remain preliminary, Patel noted that the therapy targets a specific mechanism that could potentially unlock the effectiveness of immunotherapy in other cancers.
The presentation highlighted the possibility of applying this approach to more common tumors, such as pancreatic and ovarian cancers, which have historically resisted immunotherapy efforts. Patel stated at the conference that the findings can be taken forward into other areas of oncology. The company’s next step involves seeking approval for the medicine.